by Team Small News | May 6, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals’ subsidiary, Ichnos Glenmark Innovation (IGI), has received a “fast track” designation from the United States Food and Drug Administration (USFDA) for its investigational therapy, ISB 2001. This therapy is intended for the... by Team Small News | Apr 30, 2025 | Glenmark, Pharma
The UK Court of Appeal has overturned an earlier decision, granting AstraZeneca’s request for an injunction against Glenmark Pharmaceuticals’ generic version of the diabetes treatment Forxiga (dapagliflozin). This decision comes as a significant setback...
by Team Small News | Apr 15, 2025 | Glenmark, Pharma, Sun Pharma, Zydus
Three major Indian pharmaceutical companies, Sun Pharma, Zydus, and Glenmark, have issued recalls of their products in the United States due to manufacturing issues. The recalls were announced by the US Food and Drug Administration (FDA) and cover a range of products,... by Team Small News | Apr 11, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals has received a nod from a CDSCO (Central Drugs Standard Control Organization) panel to conduct clinical trials in India for its new investigational drug combination, Glycopyrronium, Fluticasone Furoate, Vilanterol Powder for Inhalation. This... by Team Small News | Apr 3, 2025 | Glenmark, Pharma
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is a India-based company that develops and manufactures non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company provides contract development and... by Team Small News | Apr 2, 2025 | Glenmark, Pharma
Glenmark has announced the launch of its generic version of Mylan’s Vancomycin Hydrochloride for Injection, which is now available in three concentrations: 750 mg/vial, 1.25 g/vial, and 1.5 g/vial (Single-dose vial). According to IQVIA, the market value of...